Uringebundene Diagnostik. Ein Update der Kieler Tumorbank

Translated title of the contribution: Urine-based diagnostics. An update on the Kiel Tumor Bank

S. Hautmann, Vinata B Lokeshwar, K. P. Juenemann

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The heterogeneity of bladder tumors in their ability to invade and metastasize and their frequent recurrence pose a challenge for physicians who treat bladder cancer patients and for the researchers who work on bladder cancer diagnosis, recurrence, and treatment-related areas. For most new bladder cancer cases, investigation begins when patients are symptomatic (i.e., hematuria or irritative voiding). This mode of detection is often inadequate for nearly 15-30% of these new cases with high-grade bladder cancer, since the tumor is already in the invasive stage at the time of diagnosis. Bladder cancer patients are on a mandatory 3-month to 6-month surveillance schedule because bladder tumors frequently recur. The current mode of detecting bladder cancer involves cystoscopy, which is an invasive and relatively expensive procedure. Voided urine cytology, the standard noninvasive marker, is highly tumor specific and has good sensitivity for detecting high-grade tumors. However, its sensitivity for detecting low-grade tumors is low; its accuracy depends on the examiner's expertise; and it is not available everywhere. Marker systems are readily available for use in practice. Their utility remains under discussion.

Original languageGerman
Pages (from-to)619-624
Number of pages6
JournalUrologe - Ausgabe A
Volume48
Issue number6
DOIs
StatePublished - Jun 1 2009
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Urine
Neoplasms
Recurrence
Cystoscopy
Hematuria
Cell Biology
Appointments and Schedules
Research Personnel
Physicians

Keywords

  • Bladder cancer
  • Urine cytology
  • Urine marker

ASJC Scopus subject areas

  • Urology

Cite this

Uringebundene Diagnostik. Ein Update der Kieler Tumorbank. / Hautmann, S.; Lokeshwar, Vinata B; Juenemann, K. P.

In: Urologe - Ausgabe A, Vol. 48, No. 6, 01.06.2009, p. 619-624.

Research output: Contribution to journalReview article

Hautmann, S. ; Lokeshwar, Vinata B ; Juenemann, K. P. / Uringebundene Diagnostik. Ein Update der Kieler Tumorbank. In: Urologe - Ausgabe A. 2009 ; Vol. 48, No. 6. pp. 619-624.
@article{3fdba6618cc94b2b8a4aebd152d40003,
title = "Uringebundene Diagnostik. Ein Update der Kieler Tumorbank",
abstract = "The heterogeneity of bladder tumors in their ability to invade and metastasize and their frequent recurrence pose a challenge for physicians who treat bladder cancer patients and for the researchers who work on bladder cancer diagnosis, recurrence, and treatment-related areas. For most new bladder cancer cases, investigation begins when patients are symptomatic (i.e., hematuria or irritative voiding). This mode of detection is often inadequate for nearly 15-30{\%} of these new cases with high-grade bladder cancer, since the tumor is already in the invasive stage at the time of diagnosis. Bladder cancer patients are on a mandatory 3-month to 6-month surveillance schedule because bladder tumors frequently recur. The current mode of detecting bladder cancer involves cystoscopy, which is an invasive and relatively expensive procedure. Voided urine cytology, the standard noninvasive marker, is highly tumor specific and has good sensitivity for detecting high-grade tumors. However, its sensitivity for detecting low-grade tumors is low; its accuracy depends on the examiner's expertise; and it is not available everywhere. Marker systems are readily available for use in practice. Their utility remains under discussion.",
keywords = "Bladder cancer, Urine cytology, Urine marker",
author = "S. Hautmann and Lokeshwar, {Vinata B} and Juenemann, {K. P.}",
year = "2009",
month = "6",
day = "1",
doi = "10.1007/s00120-009-1991-7",
language = "German",
volume = "48",
pages = "619--624",
journal = "Der Urologe",
issn = "0340-2592",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Uringebundene Diagnostik. Ein Update der Kieler Tumorbank

AU - Hautmann, S.

AU - Lokeshwar, Vinata B

AU - Juenemann, K. P.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - The heterogeneity of bladder tumors in their ability to invade and metastasize and their frequent recurrence pose a challenge for physicians who treat bladder cancer patients and for the researchers who work on bladder cancer diagnosis, recurrence, and treatment-related areas. For most new bladder cancer cases, investigation begins when patients are symptomatic (i.e., hematuria or irritative voiding). This mode of detection is often inadequate for nearly 15-30% of these new cases with high-grade bladder cancer, since the tumor is already in the invasive stage at the time of diagnosis. Bladder cancer patients are on a mandatory 3-month to 6-month surveillance schedule because bladder tumors frequently recur. The current mode of detecting bladder cancer involves cystoscopy, which is an invasive and relatively expensive procedure. Voided urine cytology, the standard noninvasive marker, is highly tumor specific and has good sensitivity for detecting high-grade tumors. However, its sensitivity for detecting low-grade tumors is low; its accuracy depends on the examiner's expertise; and it is not available everywhere. Marker systems are readily available for use in practice. Their utility remains under discussion.

AB - The heterogeneity of bladder tumors in their ability to invade and metastasize and their frequent recurrence pose a challenge for physicians who treat bladder cancer patients and for the researchers who work on bladder cancer diagnosis, recurrence, and treatment-related areas. For most new bladder cancer cases, investigation begins when patients are symptomatic (i.e., hematuria or irritative voiding). This mode of detection is often inadequate for nearly 15-30% of these new cases with high-grade bladder cancer, since the tumor is already in the invasive stage at the time of diagnosis. Bladder cancer patients are on a mandatory 3-month to 6-month surveillance schedule because bladder tumors frequently recur. The current mode of detecting bladder cancer involves cystoscopy, which is an invasive and relatively expensive procedure. Voided urine cytology, the standard noninvasive marker, is highly tumor specific and has good sensitivity for detecting high-grade tumors. However, its sensitivity for detecting low-grade tumors is low; its accuracy depends on the examiner's expertise; and it is not available everywhere. Marker systems are readily available for use in practice. Their utility remains under discussion.

KW - Bladder cancer

KW - Urine cytology

KW - Urine marker

UR - http://www.scopus.com/inward/record.url?scp=68149124460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68149124460&partnerID=8YFLogxK

U2 - 10.1007/s00120-009-1991-7

DO - 10.1007/s00120-009-1991-7

M3 - Review article

C2 - 19557467

AN - SCOPUS:68149124460

VL - 48

SP - 619

EP - 624

JO - Der Urologe

JF - Der Urologe

SN - 0340-2592

IS - 6

ER -